nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—SLC22A6—Hydrochlorothiazide—nephrolithiasis	0.473	1	CbGbCtD
Naproxen—SLC22A6—Organic anion transport—SLC22A12—nephrolithiasis	0.0242	0.189	CbGpPWpGaD
Naproxen—UGT1A1—urine—nephrolithiasis	0.018	0.183	CbGeAlD
Naproxen—SLC22A6—Organic cation/anion/zwitterion transport—SLC22A12—nephrolithiasis	0.0113	0.0878	CbGpPWpGaD
Naproxen—ALB—Scavenging of heme from plasma—AMBP—nephrolithiasis	0.0112	0.0869	CbGpPWpGaD
Naproxen—PTGS2—nephron—nephrolithiasis	0.00821	0.0836	CbGeAlD
Naproxen—CYP1A2—urine—nephrolithiasis	0.00795	0.0809	CbGeAlD
Naproxen—CYP2C9—urine—nephrolithiasis	0.00755	0.0768	CbGeAlD
Naproxen—Epigastric pain—Hydrochlorothiazide—nephrolithiasis	0.00726	0.0242	CcSEcCtD
Naproxen—Anorectal disorder—Hydrochlorothiazide—nephrolithiasis	0.00667	0.0222	CcSEcCtD
Naproxen—Serum creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.0057	0.019	CcSEcCtD
Naproxen—Respiratory distress—Hydrochlorothiazide—nephrolithiasis	0.00552	0.0184	CcSEcCtD
Naproxen—Peptic ulcer—Hydrochlorothiazide—nephrolithiasis	0.00525	0.0175	CcSEcCtD
Naproxen—AKR1C3—nephron tubule—nephrolithiasis	0.00524	0.0534	CbGeAlD
Naproxen—SLC22A6—nephron tubule—nephrolithiasis	0.00522	0.0531	CbGeAlD
Naproxen—Nephritis interstitial—Hydrochlorothiazide—nephrolithiasis	0.0052	0.0173	CcSEcCtD
Naproxen—UGT2B7—renal system—nephrolithiasis	0.00517	0.0526	CbGeAlD
Naproxen—Heartburn—Hydrochlorothiazide—nephrolithiasis	0.0051	0.017	CcSEcCtD
Naproxen—UGT2B7—kidney—nephrolithiasis	0.005	0.0508	CbGeAlD
Naproxen—Tubulointerstitial nephritis—Hydrochlorothiazide—nephrolithiasis	0.00458	0.0153	CcSEcCtD
Naproxen—AKR1C3—cortex of kidney—nephrolithiasis	0.00449	0.0457	CbGeAlD
Naproxen—SLC22A6—cortex of kidney—nephrolithiasis	0.00447	0.0455	CbGeAlD
Naproxen—ALB—Binding and Uptake of Ligands by Scavenger Receptors—AMBP—nephrolithiasis	0.00446	0.0347	CbGpPWpGaD
Naproxen—UGT1A1—renal system—nephrolithiasis	0.00439	0.0447	CbGeAlD
Naproxen—Glycosuria—Hydrochlorothiazide—nephrolithiasis	0.00433	0.0144	CcSEcCtD
Naproxen—UGT1A1—kidney—nephrolithiasis	0.00425	0.0432	CbGeAlD
Naproxen—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.00391	0.013	CcSEcCtD
Naproxen—Hyperuricaemia—Hydrochlorothiazide—nephrolithiasis	0.00378	0.0126	CcSEcCtD
Naproxen—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.00378	0.0126	CcSEcCtD
Naproxen—Hypercholesterolaemia—Hydrochlorothiazide—nephrolithiasis	0.00371	0.0124	CcSEcCtD
Naproxen—Bone pain—Hydrochlorothiazide—nephrolithiasis	0.00366	0.0122	CcSEcCtD
Naproxen—Vasculitis—Hydrochlorothiazide—nephrolithiasis	0.0036	0.012	CcSEcCtD
Naproxen—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.00357	0.0119	CcSEcCtD
Naproxen—Coordination abnormal—Hydrochlorothiazide—nephrolithiasis	0.00357	0.0119	CcSEcCtD
Naproxen—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.00345	0.0115	CcSEcCtD
Naproxen—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.00341	0.0114	CcSEcCtD
Naproxen—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.00331	0.011	CcSEcCtD
Naproxen—Aplastic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00329	0.011	CcSEcCtD
Naproxen—Oesophagitis—Hydrochlorothiazide—nephrolithiasis	0.00321	0.0107	CcSEcCtD
Naproxen—Urine output increased—Hydrochlorothiazide—nephrolithiasis	0.00317	0.0106	CcSEcCtD
Naproxen—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.00317	0.0106	CcSEcCtD
Naproxen—Pulmonary oedema—Hydrochlorothiazide—nephrolithiasis	0.00312	0.0104	CcSEcCtD
Naproxen—SLCO1A2—renal system—nephrolithiasis	0.00298	0.0303	CbGeAlD
Naproxen—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00293	0.00976	CcSEcCtD
Naproxen—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.0029	0.00967	CcSEcCtD
Naproxen—Photosensitivity—Hydrochlorothiazide—nephrolithiasis	0.0029	0.00967	CcSEcCtD
Naproxen—Swelling—Hydrochlorothiazide—nephrolithiasis	0.00289	0.00962	CcSEcCtD
Naproxen—SLCO1A2—kidney—nephrolithiasis	0.00288	0.0293	CbGeAlD
Naproxen—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.00287	0.00958	CcSEcCtD
Naproxen—Vascular purpura—Hydrochlorothiazide—nephrolithiasis	0.00285	0.00949	CcSEcCtD
Naproxen—Haemolytic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00282	0.0094	CcSEcCtD
Naproxen—UGT2B7—Phase II conjugation—SLC26A1—nephrolithiasis	0.00278	0.0216	CbGpPWpGaD
Naproxen—Dermatitis exfoliative—Hydrochlorothiazide—nephrolithiasis	0.0027	0.009	CcSEcCtD
Naproxen—Visual disturbance—Hydrochlorothiazide—nephrolithiasis	0.00269	0.00896	CcSEcCtD
Naproxen—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.00268	0.00892	CcSEcCtD
Naproxen—Thirst—Hydrochlorothiazide—nephrolithiasis	0.00268	0.00892	CcSEcCtD
Naproxen—Purpura—Hydrochlorothiazide—nephrolithiasis	0.00264	0.00881	CcSEcCtD
Naproxen—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00255	0.00849	CcSEcCtD
Naproxen—Migraine—Hydrochlorothiazide—nephrolithiasis	0.00251	0.00836	CcSEcCtD
Naproxen—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.00251	0.00836	CcSEcCtD
Naproxen—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.00241	0.00804	CcSEcCtD
Naproxen—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00239	0.00795	CcSEcCtD
Naproxen—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.00235	0.00784	CcSEcCtD
Naproxen—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00233	0.00778	CcSEcCtD
Naproxen—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.00233	0.00775	CcSEcCtD
Naproxen—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.00232	0.00773	CcSEcCtD
Naproxen—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.0023	0.00767	CcSEcCtD
Naproxen—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.00229	0.00764	CcSEcCtD
Naproxen—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00229	0.00764	CcSEcCtD
Naproxen—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00226	0.0176	CbGpPWpGaD
Naproxen—UGT1A1—Phase II conjugation—SLC26A1—nephrolithiasis	0.00226	0.0176	CbGpPWpGaD
Naproxen—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.00225	0.00751	CcSEcCtD
Naproxen—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.00225	0.00749	CcSEcCtD
Naproxen—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.00222	0.00739	CcSEcCtD
Naproxen—Influenza—Hydrochlorothiazide—nephrolithiasis	0.0022	0.00734	CcSEcCtD
Naproxen—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.0022	0.00734	CcSEcCtD
Naproxen—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.00216	0.00719	CcSEcCtD
Naproxen—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00214	0.00715	CcSEcCtD
Naproxen—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.0021	0.0164	CbGpPWpGaD
Naproxen—CYP2C8—renal system—nephrolithiasis	0.00208	0.0212	CbGeAlD
Naproxen—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00206	0.00686	CcSEcCtD
Naproxen—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00203	0.00678	CcSEcCtD
Naproxen—CYP2C8—kidney—nephrolithiasis	0.00201	0.0205	CbGeAlD
Naproxen—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00201	0.0067	CcSEcCtD
Naproxen—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00199	0.00662	CcSEcCtD
Naproxen—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00197	0.00658	CcSEcCtD
Naproxen—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00195	0.00649	CcSEcCtD
Naproxen—CYP1A2—renal system—nephrolithiasis	0.00195	0.0198	CbGeAlD
Naproxen—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00194	0.00645	CcSEcCtD
Naproxen—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00193	0.00643	CcSEcCtD
Naproxen—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.00192	0.00641	CcSEcCtD
Naproxen—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00192	0.00641	CcSEcCtD
Naproxen—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00191	0.00638	CcSEcCtD
Naproxen—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00191	0.00636	CcSEcCtD
Naproxen—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00191	0.00636	CcSEcCtD
Naproxen—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00188	0.00627	CcSEcCtD
Naproxen—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00187	0.00624	CcSEcCtD
Naproxen—UGT2B7—NRF2 pathway—SLC2A9—nephrolithiasis	0.00185	0.0144	CbGpPWpGaD
Naproxen—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00185	0.00617	CcSEcCtD
Naproxen—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00184	0.00614	CcSEcCtD
Naproxen—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.00183	0.00611	CcSEcCtD
Naproxen—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00177	0.00589	CcSEcCtD
Naproxen—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00176	0.00587	CcSEcCtD
Naproxen—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00175	0.00583	CcSEcCtD
Naproxen—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00174	0.00579	CcSEcCtD
Naproxen—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.0017	0.00566	CcSEcCtD
Naproxen—PTGS1—renal system—nephrolithiasis	0.00169	0.0172	CbGeAlD
Naproxen—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00167	0.00555	CcSEcCtD
Naproxen—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00164	0.00548	CcSEcCtD
Naproxen—PTGS1—kidney—nephrolithiasis	0.00163	0.0166	CbGeAlD
Naproxen—UGT2B7—Biological oxidations—SLC26A1—nephrolithiasis	0.00162	0.0126	CbGpPWpGaD
Naproxen—PTGS2—renal system—nephrolithiasis	0.00161	0.0164	CbGeAlD
Naproxen—SLCO1A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00158	0.0123	CbGpPWpGaD
Naproxen—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00157	0.00525	CcSEcCtD
Naproxen—PTGS2—kidney—nephrolithiasis	0.00156	0.0159	CbGeAlD
Naproxen—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00156	0.00519	CcSEcCtD
Naproxen—Erythema—Hydrochlorothiazide—nephrolithiasis	0.00153	0.00511	CcSEcCtD
Naproxen—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00151	0.00504	CcSEcCtD
Naproxen—Tension—Hydrochlorothiazide—nephrolithiasis	0.00151	0.00502	CcSEcCtD
Naproxen—UGT1A1—NRF2 pathway—SLC2A9—nephrolithiasis	0.0015	0.0117	CbGpPWpGaD
Naproxen—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00149	0.00497	CcSEcCtD
Naproxen—SLC22A6—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00148	0.0115	CbGpPWpGaD
Naproxen—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00147	0.00492	CcSEcCtD
Naproxen—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00145	0.00482	CcSEcCtD
Naproxen—SLCO1A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00144	0.0112	CbGpPWpGaD
Naproxen—SLCO1A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00144	0.0112	CbGpPWpGaD
Naproxen—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00144	0.00479	CcSEcCtD
Naproxen—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00142	0.00474	CcSEcCtD
Naproxen—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00142	0.00473	CcSEcCtD
Naproxen—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.0014	0.00467	CcSEcCtD
Naproxen—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00138	0.00461	CcSEcCtD
Naproxen—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00138	0.00459	CcSEcCtD
Naproxen—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00138	0.00458	CcSEcCtD
Naproxen—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00137	0.00458	CcSEcCtD
Naproxen—SLC22A6—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00136	0.0106	CbGpPWpGaD
Naproxen—SLC22A6—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00136	0.0106	CbGpPWpGaD
Naproxen—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00136	0.00452	CcSEcCtD
Naproxen—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00135	0.00449	CcSEcCtD
Naproxen—Cough—Hydrochlorothiazide—nephrolithiasis	0.00134	0.00446	CcSEcCtD
Naproxen—UGT1A1—Biological oxidations—SLC26A1—nephrolithiasis	0.00132	0.0103	CbGpPWpGaD
Naproxen—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00131	0.00435	CcSEcCtD
Naproxen—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00131	0.00435	CcSEcCtD
Naproxen—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00131	0.00435	CcSEcCtD
Naproxen—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.0013	0.00434	CcSEcCtD
Naproxen—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00129	0.0043	CcSEcCtD
Naproxen—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00128	0.00426	CcSEcCtD
Naproxen—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00126	0.00421	CcSEcCtD
Naproxen—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00125	0.00417	CcSEcCtD
Naproxen—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00125	0.00417	CcSEcCtD
Naproxen—Shock—Hydrochlorothiazide—nephrolithiasis	0.00123	0.00411	CcSEcCtD
Naproxen—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00123	0.00409	CcSEcCtD
Naproxen—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00122	0.00407	CcSEcCtD
Naproxen—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00121	0.00403	CcSEcCtD
Naproxen—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00119	0.00398	CcSEcCtD
Naproxen—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00117	0.0039	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00114	0.0038	CcSEcCtD
Naproxen—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00113	0.00377	CcSEcCtD
Naproxen—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00112	0.00375	CcSEcCtD
Naproxen—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00112	0.00372	CcSEcCtD
Naproxen—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00111	0.00371	CcSEcCtD
Naproxen—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.0011	0.00367	CcSEcCtD
Naproxen—SLCO1A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00109	0.00851	CbGpPWpGaD
Naproxen—SLCO1A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00109	0.00851	CbGpPWpGaD
Naproxen—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00109	0.00363	CcSEcCtD
Naproxen—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00108	0.0036	CcSEcCtD
Naproxen—PTGS1—Biological oxidations—SLC26A1—nephrolithiasis	0.00108	0.00837	CbGpPWpGaD
Naproxen—Pain—Hydrochlorothiazide—nephrolithiasis	0.00107	0.00357	CcSEcCtD
Naproxen—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00107	0.00357	CcSEcCtD
Naproxen—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00103	0.00344	CcSEcCtD
Naproxen—SLC22A6—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00103	0.008	CbGpPWpGaD
Naproxen—SLC22A6—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00103	0.008	CbGpPWpGaD
Naproxen—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00102	0.00341	CcSEcCtD
Naproxen—SLCO1A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00102	0.00791	CbGpPWpGaD
Naproxen—SLCO1A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00102	0.00791	CbGpPWpGaD
Naproxen—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.000995	0.00331	CcSEcCtD
Naproxen—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00099	0.0033	CcSEcCtD
Naproxen—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00099	0.0033	CcSEcCtD
Naproxen—SLC22A6—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000955	0.00743	CbGpPWpGaD
Naproxen—SLC22A6—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000955	0.00743	CbGpPWpGaD
Naproxen—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.000922	0.00307	CcSEcCtD
Naproxen—SLCO1A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000906	0.00705	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000899	0.007	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000899	0.007	CbGpPWpGaD
Naproxen—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.000898	0.00299	CcSEcCtD
Naproxen—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.000886	0.00295	CcSEcCtD
Naproxen—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.000857	0.00285	CcSEcCtD
Naproxen—SLC22A6—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000851	0.00663	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000845	0.00658	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000845	0.00658	CbGpPWpGaD
Naproxen—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.000828	0.00276	CcSEcCtD
Naproxen—CYP1A2—Phase II conjugation—SLC26A1—nephrolithiasis	0.000826	0.00643	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—AQP1—nephrolithiasis	0.000823	0.0064	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000801	0.00624	CbGpPWpGaD
Naproxen—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.000796	0.00265	CcSEcCtD
Naproxen—Rash—Hydrochlorothiazide—nephrolithiasis	0.000789	0.00263	CcSEcCtD
Naproxen—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.000789	0.00263	CcSEcCtD
Naproxen—Headache—Hydrochlorothiazide—nephrolithiasis	0.000784	0.00261	CcSEcCtD
Naproxen—ALB—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.000771	0.006	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000753	0.00586	CbGpPWpGaD
Naproxen—Nausea—Hydrochlorothiazide—nephrolithiasis	0.000744	0.00248	CcSEcCtD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000733	0.0057	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000733	0.0057	CbGpPWpGaD
Naproxen—ALB—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.000705	0.00548	CbGpPWpGaD
Naproxen—ALB—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.000705	0.00548	CbGpPWpGaD
Naproxen—CYP2C8—Biological oxidations—SLC26A1—nephrolithiasis	0.000695	0.00541	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000689	0.00536	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000689	0.00536	CbGpPWpGaD
Naproxen—CYP2C9—Biological oxidations—SLC26A1—nephrolithiasis	0.000566	0.0044	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—GRHPR—nephrolithiasis	0.000558	0.00434	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000556	0.00432	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000556	0.00432	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ADCY10—nephrolithiasis	0.000549	0.00427	CbGpPWpGaD
Naproxen—ALB—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.000534	0.00416	CbGpPWpGaD
Naproxen—ALB—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.000534	0.00416	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000522	0.00406	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000522	0.00406	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000516	0.00402	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000516	0.00402	CbGpPWpGaD
Naproxen—AKR1C3—Disease—SLC26A1—nephrolithiasis	0.000505	0.00393	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.000504	0.00392	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—AGXT—nephrolithiasis	0.000497	0.00387	CbGpPWpGaD
Naproxen—ALB—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000497	0.00386	CbGpPWpGaD
Naproxen—ALB—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000497	0.00386	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000485	0.00378	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000485	0.00378	CbGpPWpGaD
Naproxen—CYP1A2—Biological oxidations—SLC26A1—nephrolithiasis	0.000483	0.00376	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—RGS14—nephrolithiasis	0.000466	0.00363	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00046	0.00358	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00046	0.00358	CbGpPWpGaD
Naproxen—AKR1C3—Disease—ATP6V0A4—nephrolithiasis	0.00045	0.0035	CbGpPWpGaD
Naproxen—ALB—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000443	0.00344	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000439	0.00342	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000439	0.00342	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000433	0.00337	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000433	0.00337	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—APRT—nephrolithiasis	0.000423	0.00329	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—SLC26A1—nephrolithiasis	0.000423	0.00329	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000392	0.00305	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000368	0.00286	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GRHPR—nephrolithiasis	0.000367	0.00285	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000358	0.00279	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000358	0.00279	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000346	0.00269	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—AGXT—nephrolithiasis	0.000327	0.00254	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GRHPR—nephrolithiasis	0.000319	0.00248	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000315	0.00245	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—DGKH—nephrolithiasis	0.000315	0.00245	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—AQP1—nephrolithiasis	0.000301	0.00234	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GRHPR—nephrolithiasis	0.000298	0.00232	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—AGXT—nephrolithiasis	0.000284	0.00221	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—APRT—nephrolithiasis	0.000278	0.00216	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—SLC26A1—nephrolithiasis	0.000278	0.00216	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—CHRM3—nephrolithiasis	0.000272	0.00212	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000271	0.00211	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000271	0.00211	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—AGXT—nephrolithiasis	0.000265	0.00207	CbGpPWpGaD
Naproxen—ALB—Hemostasis—DGKH—nephrolithiasis	0.00026	0.00202	CbGpPWpGaD
Naproxen—ALB—Hemostasis—SLC7A9—nephrolithiasis	0.00026	0.00202	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000252	0.00196	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000252	0.00196	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GRHPR—nephrolithiasis	0.000243	0.00189	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—SLC26A1—nephrolithiasis	0.000242	0.00188	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—APRT—nephrolithiasis	0.000242	0.00188	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CHRM3—nephrolithiasis	0.000228	0.00177	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—APRT—nephrolithiasis	0.000226	0.00176	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—SLC26A1—nephrolithiasis	0.000226	0.00176	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000225	0.00175	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000225	0.00175	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—AGXT—nephrolithiasis	0.000216	0.00168	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PTH—nephrolithiasis	0.000208	0.00162	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—AQP1—nephrolithiasis	0.000198	0.00154	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GRHPR—nephrolithiasis	0.000193	0.0015	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—SLC26A1—nephrolithiasis	0.000184	0.00143	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—APRT—nephrolithiasis	0.000184	0.00143	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00018	0.0014	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—CHRM3—nephrolithiasis	0.000179	0.00139	CbGpPWpGaD
Naproxen—PTGS2—Disease—SLC26A1—nephrolithiasis	0.000174	0.00136	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—AQP1—nephrolithiasis	0.000172	0.00134	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AGXT—nephrolithiasis	0.000172	0.00134	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—AQP1—nephrolithiasis	0.000161	0.00125	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GRHPR—nephrolithiasis	0.000157	0.00122	CbGpPWpGaD
Naproxen—ALB—Metabolism—GRHPR—nephrolithiasis	0.000156	0.00121	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CHRM3—nephrolithiasis	0.000156	0.00121	CbGpPWpGaD
Naproxen—PTGS2—Disease—ATP6V0A4—nephrolithiasis	0.000155	0.00121	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—SLC26A1—nephrolithiasis	0.000146	0.00114	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—APRT—nephrolithiasis	0.000146	0.00114	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CHRM3—nephrolithiasis	0.000145	0.00113	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AGXT—nephrolithiasis	0.00014	0.00109	CbGpPWpGaD
Naproxen—ALB—Metabolism—AGXT—nephrolithiasis	0.000139	0.00108	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—AQP1—nephrolithiasis	0.000131	0.00102	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GRHPR—nephrolithiasis	0.000128	0.000993	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—APRT—nephrolithiasis	0.000119	0.000925	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—SLC26A1—nephrolithiasis	0.000119	0.000925	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CHRM3—nephrolithiasis	0.000119	0.000923	CbGpPWpGaD
Naproxen—ALB—Metabolism—APRT—nephrolithiasis	0.000118	0.00092	CbGpPWpGaD
Naproxen—ALB—Metabolism—SLC26A1—nephrolithiasis	0.000118	0.00092	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AGXT—nephrolithiasis	0.000114	0.000885	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GRHPR—nephrolithiasis	0.000109	0.000849	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SPP1—nephrolithiasis	0.000105	0.000814	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AQP1—nephrolithiasis	0.000104	0.00081	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AGXT—nephrolithiasis	9.72e-05	0.000757	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—APRT—nephrolithiasis	9.67e-05	0.000753	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SLC26A1—nephrolithiasis	9.67e-05	0.000753	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CHRM3—nephrolithiasis	9.41e-05	0.000733	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AQP1—nephrolithiasis	8.47e-05	0.000659	CbGpPWpGaD
Naproxen—ALB—Metabolism—AQP1—nephrolithiasis	8.42e-05	0.000655	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SLC26A1—nephrolithiasis	8.27e-05	0.000643	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—APRT—nephrolithiasis	8.27e-05	0.000643	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CHRM3—nephrolithiasis	7.66e-05	0.000596	CbGpPWpGaD
Naproxen—ALB—Metabolism—CHRM3—nephrolithiasis	7.62e-05	0.000593	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AQP1—nephrolithiasis	6.89e-05	0.000536	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CHRM3—nephrolithiasis	6.23e-05	0.000485	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AQP1—nephrolithiasis	5.89e-05	0.000458	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CHRM3—nephrolithiasis	5.33e-05	0.000415	CbGpPWpGaD
